Potassium Channels: Overview of Molecular, Biophysical and Pharmacological Properties

Voltage-Gated Ion Channels as Drug Targets

Volumn 29, Issue , 2006, Pages 193-213

  Gopalakrishnan, Murali ^a   Shieh, Char Chang ^b   Chen, Jun ^b  

^a ABBOTT LABORATORIES   (United States)

^b NONE

Author keywords

Auxiliary subunits; Classification; Crystal structure; K+ channels and diseases; Ligands; Peptides and toxins; Potassium channels; Properties

Indexed keywords

CLASSIFICATION (OF INFORMATION); LIGANDS; POTASSIUM;

AUXILIARY SUBUNITS; K+ CHANNELS; PHARMACOLOGICAL PROPERTIES; POTASSIUM CHANNELS; PROPERTIES;

CRYSTAL STRUCTURE;

EID: 85018202895     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527608141.ch7a     Document Type: Chapter

References (56)

1. Hille, B., Ion Channels of Excitable Membranes. 3rd edn. 2001, Sinauer Associates, Inc., Sunderland, MA.
2. Papazian, D.M., et al. Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from Drosophila. Science 1987, 237, 749-753.
3. MacKinnon, R. Potassium channels. FEBS Lett. 2003, 555, 62-65.
4. MacKinnon, R. Potassium channels and the atomic basis of selective ion conduction. Biosci. Rep. 2004, 24, 75-100.
5. + channels. Annu. Rev. Physiol. 2004, 66, 103-129.
6. Frank, N. P., Honore, E. The TREK K2P channels and their role in general anaesthesia and neuroprotection. Trends Pharmacol. Sci. 2004, 25, 601-608.
7. + channels. Curr. Drug Targets 2003, 4, 347-351.
8. Birnbaum, S.G.V, et al. Structure and function of Kv4-family transient potassium channels. Physiol. Rev. 2004, 84, 803-833.
9. + conduction and selectivity. Science 1998, 280, 69-77.
10. Jiang, Y., et al. Crystal structure and mechanism of a calcium-gated potassium channel. Nature 2002, 417, 515-522.
11. Kuo, A., et al. Crystal structure of the potassium channel KirBac1.1 in the closed state. Science 2003, 300, 1922-1926.
12. + channel. Nature 2003, 423, 42-48.
13. Zhou, M., et al. Potassium channel receptor site for the inactivation gate and quaternary amine inhibitors. Nature 2001, 411, 657-661.
14. Jiang, Y., et al. The open pore conformation of potassium channels. Nature 2002, 417, 523-526.
15. + channel. Nature 2003, 423, 33-41.
16. Mitcheson, J.S., et al. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 12 329-12 333.
17. Liu, H., et al. Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing. Chem. Biol. 2003, 10, 1103-1113.
18. Bains, W, A. Basman, C. White. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog. Biophys. Mol Biol. 2004, 86, 205-233.
19. + channel blockers. J. Med. Chem. 2002, 45, 3844-3853.
20. Ekins, S., et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 2002, 301, 427-434.
21. Shieh, C.C., et al. Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol. Rev. 2000, 52, 557-594.
22. Sanguinetti, M. C., Mitcheson, J. S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 2005, 26, 119-124.
23. + channels as targets of CNS drug development. Curr. Drug Targets CNS Neurol. Disord. 2004, 3, 161-167.
24. Coghlan, M.J., WA. Carroll, M. Gopalakrishnan. Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J. Med. Chem. 2001, 44, 1627-1653.
25. + channel involved in neuroprotection and general anesthesia. EMBO J. 2004, 23, 2684-2695.
26. Armstrong, C.M. Inactivation of the potassium conductance and related phenomena caused by quaternary ammonium ion injection in squid axons. J. Gen. Physiol. 1969, 54, 553-575.
27. Armstrong, C.M. Interaction of tetra-ethylammonium ion derivatives with the potassium channels of giant axons. J. Gen. Physiol. 1971, 58, 413-437.
28. + channels: evidence for a trap door mechanism of activation gating. J. Gen. Physiol. 1997, 109, 527-535.
29. Mitcheson, J.S., J. Chen, M.C. Sanguinetti. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J. Gen. Physiol. 2000, 115, 229-240.
30. Sanguinetti, M.C., et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995, 81, 299-307.
31. + channels. Circ. Res. 1998, 82, 386-395.
32. Chen, J., G. Seebohm, M.C. Sanguinetti. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 12 461-12 466.
33. + channel block. J. Biol. Chem. 2002, 277, 23 587-23 595.
34. Sanchez-Chapula, J.A., et al. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol. Pharmacol. 2003, 63, 1051-1058.
35. + channels by vesnarinone. Mol. Pharmacol. 2001, 60, 244-253.
36. Hanner, M., et al. Binding of correolide to the Kv1.3 potassium channel: characterization of the binding domain by site-directed mutagenesis. Biochemistry 2001, 40, 11687-11697.
37. Seebohm, G., et al. Pharmacological activation of normal and arrhythmia-associated mutant KCNQ1 potassium channels. Circ. Res. 2003, 93, 941-947.
38. + channels. J. Biol. Chem. 2004, 279, 394-400.
39. Dickinson, K.E., et al., Nucleotide regulation and characteristics of potassium channel opener binding to skeletal muscle membranes. Mol. Pharmacol. 1997, 52, 473-481.
40. ATP channel modulator binding to the recombinant sulfonylurea receptor, SUR2B. Br. J. Pharmacol. 1998, 125, 577-583.
41. ATP channel openers. EMBOJ. 2000, 19, 6644-6651.
42. ATP channel openers. Mol. Pharmacol. 2005, 67, 1026-1033.
43. + channels. Mol. Pharmacol. 2004, 65, 1198-1207.
44. + channels: implication for dimerization of nucleotide-binding domains to induce channel opening. Mol. Pharmacol. 2004, 66, 807-816.
45. + channels by a novel scorpion toxin. Nature 1982, 296, 90-91.
46. + channel-blocking peptides. Neuron 1995, 15, 5-10.
47. + channels. Neuron 1997, 18, 675-682.
48. +-channels. Toxicon 2004, 43, 865-875.
49. Lee, S.Y., R. MacKinnon. A membrane-access mechanism of ion channel inhibition by voltage sensor toxins from spider venom. Nature 2004, 430, 232-235.
50. Rauer, H., et al. Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin. J. Biol. Chem. 1999, 274, 21885-21892.
51. + channel. J. Gen. Physiol. 2000, 115, 673-684.
52. Regaya, I., et al. Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins. J. Biol. Chem. 2004, 279, 55 690-55 696.
53. + channels. Proteins 2004, 56, 367-375.
54. Imredy, J.P., R. MacKinnon. Energetic and structural interactions between delta-dendrotoxin and a voltage-gated potassium channel. J. Mol. Biol. 2000, 296, 1283-1294.
55. Kalman, K., et al. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J. Biol. Chem. 1998, 273, 32 697-32 707.
56. Miljanich, G.P. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 2004, 11, 3029-3040.